The efficacy of BIIB023 (phase II) is now explored in the ongoing clinical trial ATLAS (Anti-TWEAK in Lupus Nephritis patients) for patients with lupus nephritis, a pathology that requires a more innovative treatment than RA. Here, TNFSF12 is linked to lupus nephritis.